In recent years, significant advancement has been made in the clinical application of cancer immunotherapies.
Molecules directed against immune checkpoints and other agonists show great promise for treatment of a variety of malignancies. In addition to Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) and Programmed cell death protein 1 (PD-1) blockade, a wide range of therapeutics with the potential to reverse the tumour-induced suppression are under development.
Despite the first successes, only a relatively small portion of patients benefit from these treatments and it has been shown that combination therapies can improve the outcome.
Download to find out more.